AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03496896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TARGET
Description: The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
Study NCT05362617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
Study NCT05362617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
Study NCT04028609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy at Home
Description: In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.
Study NCT04028609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Routine medical services
Study NCT01710579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anorectal 3D-high resolution manometry
Description: Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
Study NCT01710579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anorectal radial endosonography (rotative 360° probe)
Description: Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
Study NCT01710579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic anorectal endosonography (sagittal and radial)
Description: Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
Study NCT01871844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (500, 1000, 2000 mcg bid for 7 days)
Study NCT01871844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide 50 mcg tid
Study NCT01871844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00105079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 1000 milligram (mg) Oral (po) twice daily (bid)
Study NCT00105079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 400/100 mg po bid
Study NCT00105079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
Study NCT00105079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
Study NCT00105079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg po bid
Study NCT00425750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
Study NCT00425750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
Study NCT00425750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Tissue and blood collection.
Study NCT00425750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Blood collection.
Study NCT04283630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary nitrate in the form of beetroot juice for all participnats
Description: participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.
Study NCT04283630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary nitrate in the form of beetroot juice for all participnats
Description: participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.
Study NCT04283630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nature Made vitamin c 1000 mg
Description: vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the daily vitamin C supplement (1000 mg) or placebo one-hour post beetroot juice supplementation.
Study NCT01968239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: comparison of different re-treatment criteria for intravitreal injection of ranibizumab
Study NCT04283630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin C matched Placebo capsules that made from starch.
Study NCT00775229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: pill, by mouth, 50mg-150mg/day for the duration of the study
Study NCT00775229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill, by mouth, daily
Study NCT01435460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.2%
Description: 1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
Study NCT01435460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.1%
Description: 1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
Study NCT00586820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
Study NCT00586820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
Study NCT03067532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: existed simulation system user
Description: Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
Study NCT03067532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home made simulator user
Description: Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
Study NCT03319732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Description: Arbaclofen is the active R enantiomer of baclofen.
Study NCT02984865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfentanyl
Study NCT02984865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Study NCT02984865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flubiprofen axetil
Study NCT02984865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flubiprofen axetil
Study NCT02984865 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: rectus sheath block
Description: Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
Study NCT02908165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional TACE in combination with sorafenib, administered on a continuous schedule
Description: Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
Study NCT02908165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional TACE in combination with sorafenib, administered on a sequential schedule
Description: Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
Study NCT01968239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: comparison of different re-treatment criteria for intravitreal injection of ranibizumab
Study NCT02039050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT02039050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium
Study NCT03580876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: addition of azathioprine
Description: impact of addition of azathioprine after a switch of a second anti-TNF agent
Study NCT03580876 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Switch to a second anti-TNF drug alone
Description: Switch to a second anti-TNF drug alone without addition of azathioprine
Study NCT01479465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: SIM administered via intravenous infusion over 30 minutes
Study NCT01939028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node mapping
Description: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
Study NCT01939028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo SLN biopsy
Study NCT01479465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SIM
Description: Placebo to match SIM administered via intravenous infusion over 30 minutes
Study NCT01479465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours
Study NCT01479465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes
Study NCT01939028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosulfan blue
Description: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
Study NCT01939028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
Study NCT00281983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00281983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00281983 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03681171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Dance
Description: Participants attended therapeutic ballet sessions three times per week for six weeks.
Study NCT01939028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
Study NCT01939028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: Undergo para-aortic lymphadenectomy
Study NCT03282227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M207 Microneedle System
Description: M207 Microneedle System 3.8 mg
Study NCT02792075 — intervention group
Intervention type: OTHER
Intervention: 5-year Follow-up
Study NCT01319448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proguanil
Description: Proguanil tablets, 1.5mg/kg/day
Study NCT01319448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine plus artesunate
Description: This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
Study NCT01319448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine
Description: amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
Study NCT04333667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
Study NCT04519918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AOA
Description: AOA represents an invasive non-physiological technique.
Study NCT04582630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: omega 3 fatty acid
Description: Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
Study NCT03362905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine topical
Description: Local anesthetic for reduction of IUD associated pain
Study NCT03362905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: Local anesthetic for reduction of IUD associated pain
Study NCT01764945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Reference)
Description: soft gelatine capsule, oral administration
Study NCT01764945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 3
Study NCT01764945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 2
Study NCT01764945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 (Test)
Description: oral solution 1
Study NCT00607334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-learning
Description: Exposure to five nonwords for three sessions of controlled interaction with the experimenter
Study NCT01870141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: 1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~* self-monitoring~* problem solving~* goal definition~* cognitive restructuring~* activation of personal and social resources
Study NCT04179487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OPTICA CTPA Protocol
Description: Low dose CT pulmonary angiogram protocol
Study NCT01650753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Powder
Description: Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10\^10 cells/sachet)
Study NCT01650753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
Study NCT02815553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy
Study NCT02815553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Transthoracic Cardiac Tumor Laser Ablation Therapy
Study NCT00526123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symmetric Tip Catheter
Description: Dialysis catheter
Study NCT00526123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Split-tip Catheter
Description: Dialysis Catheter
Study NCT03273946 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate
Description: Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
Study NCT02638038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131
Description: INT- 131
Study NCT02638038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INT131
Description: INT- 131
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given as previously prescribed
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given by mouth
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given by mouth
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given as previously prescribed
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given as previously prescribed
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given by mouth
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given by mouth
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given by mouth
Study NCT00687648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Given by mouth
Study NCT04210817 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT03310151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imagined movements
Description: Imagined wrist movements, 10-15 minutes, 4 times a day.
Study NCT01913067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Intravenous, 25 mg/m2 every 3 weeks
Study NCT01913067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced whole brain MRI
Description: Evaluation of the volumetric reduction in the size of the brain lesion(s).
Study NCT04290754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH-IT
Description: Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
Study NCT04290754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TEAMS
Description: Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.